Hepatitis C Virus is a viral infection that causes liver inflammation, sometimes leading to serious liver damage. It is caused by the hepatitis C virus (HCV) and is a major cause of liver cancer.
&nbsp;
The HCV is a blood-borne virus. The most common modes of infection are via exposure to small quantities of blood. This may occur via injection drug use, unsafe injection practices, unsafe health care, transfusion of unscreened blood and blood products, and sexual practices that lead to blood exposure.
&nbsp;
Hepatitis C Virus Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Hepatitis C Virus in 7MM from 2017 to 2030 is segmented as:-
<ul>
<li>Total Prevalent Cases</li>
<li>Total Diagnosed Cases</li>
<li>Total Gender-specific Cases</li>
<li>Age-specific Diagnosed Cases</li>
<li>Genotype-specific Diagnosed Cases</li>
<li>Diagnosed Cases of HCV by Impact on Liver</li>
<li>Treated Cases of HCV</li>
</ul>
&nbsp;
Hepatitis C Virus Epidemiology&nbsp;
<ul>
<li>The total prevalent cases of Hepatitis C Virus in 7MM in 2017 were 8,257,162&nbsp;&nbsp;</li>
<li>Hepatitis C Virus prevalent cases in the US in 2017 were 3,251,471</li>
</ul>
&nbsp;
<a style="color: #0066cc; background-color: transparent;" href="https://www.delveinsight.com/report-store/hepatitis-c-virus-market" target="_blank" rel="noopener noreferrer">Hepatitis C Virus Market</a>
The therapeutic market of Hepatitis C Virus in 7MM in 2017 was USD 10,445 million
&nbsp;
Hepatitis C Virus Market Drivers
<ul>
<li>Progression of DAA therapies in the form of Pan-genotypic drugs.</li>
<li>Increase in patient awareness will lead to an increase in the diagnosis rate.</li>
</ul>
&nbsp;
Hepatitis C Virus Market Barriers
<ul>
<li>The high cost of DAA Therapies</li>
<li>Lack of awareness and knowledge of disease</li>
<li>The patient population are shrinking due to high cure rates of current DAAs drugs</li>
</ul>
&nbsp;
Hepatitis C Virus Emerging Drugs
The emerging drugs of the Hepatitis C Virus market are
<ul>
<li>CC-31244 (CDI-31244)</li>
<li>AT-527</li>
<li>PRI-724 (OP-724)</li>
<li>AT-777</li>
<li>HCVax (Therapeutic HCV vaccine)</li>
</ul>
And many others.
&nbsp;
Hepatitis C Virus Key Players
The key players in the Hepatitis C Virus market are
<ul>
<li>Cocrystal Pharma</li>
<li>Atea Pharmaceuticals</li>
<li>PRISM Pharma and Ohara Pharmaceuticals</li>
<li>Atea Pharmaceuticals</li>
<li>GeneCure Biotechnologies</li>
</ul>
And many others.

Hepatitis C Virus Market

Hepatitis C Virus Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.